The Anti-Allergic Effects of a Cromolyn Sodium-Chlorpheniramine Combination Compared to Ketotifen in the Conjunctival Allergen Challenge Model

Abstract

Purpose

To compare the inhibitory effects of a topical combination product, cromolyn sodium (DSCG) 4% with the antihistamine, chlorpheniramine, with those of topical ketotifen 0.05% on the clinical allergic reaction induced by the conjunctival allergen challenge (CAC).

Methods

Ten allergic but non-active patients were challenged in both eyes with increasing doses of specific allergen to obtain a positive bilateral reaction (visit 1). They were then rechallenged after 1 week to confirm the allergic threshold dose response (visit 2). After 2 weeks, a third CAC was performed bilaterally 30 minutes after topical application of DSCG-chlorpheniramine in one eye and ketotifen in the contralateral eye in a double-masked fashion (visit 3). Clinical signs and symptoms were registered 5, 10, 15, and 20 minutes after challenge using the standard scoring system. Tear cytology was performed 30 minutes after challenge.

Results

Comparing the two drug effects at visit 3, DSCG-chlorpheniramine was shown to be superior to ketotifen at all time points for itching (p<0.01) and at 5 minutes for redness (p<0.01). For the total signs score, DSCG-chlorpheniramine was shown to be superior to ketotifen at all time points (p<0.01), and at 10 and 15 minutes for the total symptoms score (p<0.05). Compared to visit 2, DSCG-chlorpheniramine significantly lowered itching (p<0.001) and redness (p<0.05) at 5, 10, 15, and 20 minutes after challenge. Ketotifen significantly lowered itching at 5 and 10 minutes (p<0.001) and redness at 5, 10, and 15 minutes (p<0.05). Both drugs reduced the total number of cells evaluated by tear cytology during the early-phase reaction (p<0.05).

Conclusions

DSCG-chlorpheniramine was found to be more effective than ketotifen at preventing itching and redness in the CAC model.

Keywords

Allergic conjunctivitis Conjunctival allergen challenge Chlorpheniramine Sodium cromolyn Ketotifen

Get full access to this article

View all access options for this article.

References

Abelson

M.B.

Schaefer

. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993; 38(Suppl): S115–32.

Abelson

M.B.

Chambers

W.A.

Smith

L.M.

. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990; 108: 84–8.

Galli

S.F.

Costa

J.J.

. Mast-cell-leukocyte cytokine cascades in allergic inflammation. Allergy 1994; 24: 203–6.

Proud

Sweet

Stein

Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen.

J Allergy Clin Immunol 1990; 85: 896–905.

Ciprandi

Buscaglia

Pesce

G.P.

Villaggio

Bagnasco

Canonica

G.W.

. Allergic subjects express intercellular adhesion molecule 1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993; 91: 783–92.

Leonardi

. Role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand 2000; 78: 18–21.

Church

M.K.

Holgate

S.T.

Shute

J.K.

Walls

A.F.

Sampson

A.P.

. Mast cell-derived mediators. In: Middleton

Jr. Reed

C.E.

Ellis

E.F.

Adkinson

Jr. Yunginger

J.W.

Busse

W.W.

, eds. Allergy, principles and practice. St. Louis: Mosby, 1998: 146–67.

Abelson

M.B.

Wun

P.J.

Nevius

J.M.

. Mast cell stabilizers. In: Abelson

M.B.

, ed. Allergic diseases of the eye. Philadelphia: Saunders, 2000: 228–34.

Abelson

M.B.

Shaefer

Wun

P.J.

. Antihistamines and antihistamine/vasoconstrictors. In: Abelson

M.B.

, ed. Allergic diseases of the eye. Philadelphia: Saunders, 2000: 202–10.

10.

Allansmith

M.R.

Ross

R.N.

. Ocular allergy and mast cell stabilizers. Surv Ophthalmol 1986; 30: 229–44.

11.

Estelle

Simons

. Antihistamines. In: Middleton

Jr. Reed

C.E.

Ellis

E.F.

Adkinson

Jr. Yunginger

J.W.

Busse

W.W.

, eds. Allergy, principles and practice. St. Louis: Mosby, 1998: 612–37.

12.

Cerqueti

P.M.

Ciprandi

. Sperimentazione dell'associazione disodiocromoglicato-clorfenamina nel trattamento della congiuntivite allergica. Boll Ocul 1986; 65: 69–73.

13.

Grant

S.M.

Goa

K.L.

Fitton

Sorkin

E.M.

. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990; 40: 412–40.

14.

Abelson

M.B.

. Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis. Acta Ophthalmol Scand 1999; 77: 38–42.

15.

D'Arienzo

P.A.

Leonardi

Bensch

. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2002; 24: 409–16.

16.

Sharif

N.A.

S.X.

Yanni

J.M.

. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol 1994; 10: 653–64.

17.

Tasaka

Mio

Okamoto

. Intracellular calcium release induced by histamine releasers and its inhibition by some antiallergic drugs. Ann Allergy 1986; 56: 464–9.

18.

Hingorani

Lightman

. Therapeutic options in ocular allergic diseases. Drugs 1995; 50: 208–21.

19.

Bruijnzeel

P.L.

Warringa

R.A.J.

Kok

P.T.

Kreukniet

. Inhibition of neutrophil and eosinophils induced chemo-taxis by nedocromil sodium and sodium cromoglycate. Br J Pharmacol 1990; 99: 798–802.

20.

Kay

A.B.

Walsh

G.M.

Moqbel

Disodium cromoglycate inhibits activation of human inflammatory cells in vitro.

J Allergy Clin Immunol 1987; 80: 1–8.

21.

Petrasch

van Tits

L.J.

Motulky

H.J.

Brodde

O.E.

Michel

M.C.

. Effect of ketotifen on human lymphocytes in vitro and in vivo. Arzneimittelforschung 1993; 43: 904–8.

22.

Secchi

A.G.

De Liberato

Della Dora

Corbetta

. Prevenzione farmacologica della liberazione di istamina lacrimale indotta da stimolazione congiuntivale con allergeni specifici. Boll Ocul 1984; 63: 1–7.